XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. [electronic resource]
Producer: 20090219Description: 332 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Breast Neoplasms, Male -- drug therapy
- Docetaxel
- Double-Blind Method
- Doxorubicin -- adverse effects
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor -- adverse effects
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Neutropenia -- chemically induced
- Neutrophils -- drug effects
- Recombinant Proteins
- Taxoids -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.